Scalable production of lipid nanoparticles for effective gene delivery

Cell & Gene Therapy Insights 2022; 8(7), 975;

DOI: 10.18609/cgti.2022.143

Published: 12 October 2022
Reka Geczy

Watch the video or read the poster to learn more about: 

  • Pros and cons of current gene delivery mechanisms and the need for improved solutions
  • Benefits of LNPs for effective delivery of nucleic acids for gene therapy, gene editing, and mRNA vaccine applications
  • How process innovation is enabling rapid, scalable, and reproducible LNP production

  • Case study: optimizing mRNA-LNP formulations for CAR T cell editing

Reka holds a PhD in Pharmaceutical Sciences from the University of British Columbia with high impact publications at the interface of microfluidics and drug delivery. After her postdoc at the University of Copenhagen, she joined Precision NanoSystems as a Product Development Scientist. Her team is developing potent and efficient lipid nanoparticle compositions for cell therapy, currently focusing on CAR T cancer therapy. Like many teams at Precision NanoSystems, Reka and her team routinely uses the NanoAssemblr® Spark™ to advance early-stage research.